Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12.
Zhong, C., Wang, J., Li, B., Xiang, H., Ultsch, M., Coons, M., Wong, T., Chiang, N.Y., Clark, S., Clark, R., Quintana, L., Gribling, P., Suto, E., Barck, K., Corpuz, R., Yao, J., Takkar, R., Lee, W.P., Damico-Beyer, L.A., Carano, R.D., Adams, C., Kelley, R.F., Wang, W., Ferrara, N.(2013) Clin Cancer Res 19: 4433-4445
- PubMed: 23812669 
- DOI: https://doi.org/10.1158/1078-0432.CCR-13-0943
- Primary Citation of Related Structures:  
4LMQ - PubMed Abstract: 
Our goal was to develop a potent humanized antibody against mouse/human CXCL12. This report summarized its in vitro and in vivo activities.
Organizational Affiliation: 
Genentech, Inc., South San Francisco, California, USA.